Tuesday, May 30, 2023
[email protected]
 Fintech Zoom
  • MARKETS
    • Trading
    • Stock Futures
    • Exchange Traded Fund (ETF)
    • Best Stocks To Buy Now
    • Penny Stocks
    • Forex Market
    • Bonds & Rates
    • Stock Market Guides
    • Commodities
      • Brent Crude Oil Price
      • WTI Crude Oil Price
    • Breaking Stock Market News
    • Reviews in Stock Market
    • Asian Markets
    • European Markets
    • US Markets
  • WORLD INDICES
    • DAX PERFORMANCE-INDEX
    • Russel 2000 (RUT)
    • STOXX Europe 600 (SXXP)
    • Euro Stoxx 50
    • CAC 40 Index (FCHI)
    • FTSE 100 Index
    • Nikkei 225 Index
    • HSI – Hang Seng Index
    • NSE Nifty 50 Index
    • NASDAQ Composite Index
    • Dow Jones (INDEXDJX: .DJI)
    • S&P 500 Index
    • ASX – Australian
    • Shanghai Index (SSE)
  • BUSINESS
  • CRYPTO
    • Metaverse
    • Tokens
    • Crypto Reviews
    • NFT : Non-Fungible Tokens
    • Stablecoins
    • Blockchain
    • Ethereum
    • Buy Bitcoin
    • Best Crypto
    • Bitcoin
    • Altcoins
  • MONEY
    • Insurance
    • Taxes
    • Mortgages
    • Loans
    • Personal Finances
    • Credit Cards
    • Interest Rates
  • BANKING
    • Banks Near Me
    • Payments
    • ATM Near me
    • Best Banks
    • Banks Guides
    • Transfer Money Online
    • Mobile Banking
    • Digital Bank
    • Secure Bank Login
  • TECH
    • Social Media
    • Login
    • Error Pages
    • Is It Down?
    • Download
    • Settings
  • LUXURY
    • Luxury Food & Drink
    • Luxury Cars
    • Luxury Style
    • Luxury Motors
    • Luxury Travel
    • Luxury Tech
  • LIFESTYLE
    • Travel
    • Entertainment
    • Health
    • Cars
    • Near Me
    • Life
    • Weather Tomorrow
  • INVESTMENT
    • Real Estate
    • Famous Investors
  • ABOUT US
    • Why Fintech Zoom?
    • What is FintechZoom?
    • Advertise with Us
    • Careers in FintechZoom
    • Fintech Zoom Logo
    • FintechZoom PRO
    • FintechZoom Contacts
No Result
View All Result
  • MARKETS
    • Trading
    • Stock Futures
    • Exchange Traded Fund (ETF)
    • Best Stocks To Buy Now
    • Penny Stocks
    • Forex Market
    • Bonds & Rates
    • Stock Market Guides
    • Commodities
      • Brent Crude Oil Price
      • WTI Crude Oil Price
    • Breaking Stock Market News
    • Reviews in Stock Market
    • Asian Markets
    • European Markets
    • US Markets
  • WORLD INDICES
    • DAX PERFORMANCE-INDEX
    • Russel 2000 (RUT)
    • STOXX Europe 600 (SXXP)
    • Euro Stoxx 50
    • CAC 40 Index (FCHI)
    • FTSE 100 Index
    • Nikkei 225 Index
    • HSI – Hang Seng Index
    • NSE Nifty 50 Index
    • NASDAQ Composite Index
    • Dow Jones (INDEXDJX: .DJI)
    • S&P 500 Index
    • ASX – Australian
    • Shanghai Index (SSE)
  • BUSINESS
  • CRYPTO
    • Metaverse
    • Tokens
    • Crypto Reviews
    • NFT : Non-Fungible Tokens
    • Stablecoins
    • Blockchain
    • Ethereum
    • Buy Bitcoin
    • Best Crypto
    • Bitcoin
    • Altcoins
  • MONEY
    • Insurance
    • Taxes
    • Mortgages
    • Loans
    • Personal Finances
    • Credit Cards
    • Interest Rates
  • BANKING
    • Banks Near Me
    • Payments
    • ATM Near me
    • Best Banks
    • Banks Guides
    • Transfer Money Online
    • Mobile Banking
    • Digital Bank
    • Secure Bank Login
  • TECH
    • Social Media
    • Login
    • Error Pages
    • Is It Down?
    • Download
    • Settings
  • LUXURY
    • Luxury Food & Drink
    • Luxury Cars
    • Luxury Style
    • Luxury Motors
    • Luxury Travel
    • Luxury Tech
  • LIFESTYLE
    • Travel
    • Entertainment
    • Health
    • Cars
    • Near Me
    • Life
    • Weather Tomorrow
  • INVESTMENT
    • Real Estate
    • Famous Investors
  • ABOUT US
    • Why Fintech Zoom?
    • What is FintechZoom?
    • Advertise with Us
    • Careers in FintechZoom
    • Fintech Zoom Logo
    • FintechZoom PRO
    • FintechZoom Contacts
No Result
View All Result
FintechZoom
No Result
View All Result

Boom in UK medical cannabis industry: Number of users obtaining prescriptions projected to reach 337,000 by 2024

James Albert by James Albert
October 27, 2022
in Press Releases
0

Home » Boom in UK medical cannabis industry: Number of users obtaining prescriptions projected to reach 337,000 by 2024

Mamedica is the UK’s leading medicinal cannabis clinic specialising in tailored cannabis-based prescriptions, from oil to cannabis flower. The service is one of the UK’s only clinics advocating for improved accessibility to a range of medical and natural solutions and offers bespoke treatment for a number of clinical and degenerative diseases across pain, psychiatry, neurology and cancer-related conditions.

The medical cannabis industry has seen overwhelming growth since it’s legalisation in 2018, with the number of medicinal cannabis users projected to reach 337,000 in the next two years. Our understanding of its effectiveness continues to deepen as evidence continues to support its beneficial effects on several medical ailments. For example, an existing study found that from 2011 to 2015 the number of patients administered cannabis for pain relief more than doubled from 33,189 to 72,114 people – with users reporting mitigation in inflammation and improved functional outcomes. However, despite its popularity within private healthcare settings, its efficacy for management of long-term health conditions has received less attention in the public domain.  

With Medical Cannabis Awareness Week approaching in the first week of November, services such as Mamedica, are continuing to promote improved awareness, accessibility and better public knowledge about the industry. This comes amidst a new survey which reports just short of 1.8 million people in the UK with diagnosed medical conditions, ranging from anxiety disorders to chronic pain, are turning to illegally obtained cannabis to manage their illnesses. Thus, further supporting the need for enhanced education about how people can access treatment safely and securely. 

According to the Department of Health, there are eight million chronic pain sufferers in Britain, 24% of whom are typically prescribed opioids – a group of highly addictive painkillers, which has been proven to be ineffective amongst millions of chronic pain sufferers. In contrast, 80% of people who have been prescribed medical cannabis have not experienced an adverse health event since starting their treatment. Whilst the government’s stance on legalising cannabis is unabating, public support for legal cannabis in the UK is at an all-time high, as a recent survey showed that over half of Brits (52%) support the legalisation of cannabis. To this end, current arguments to keep cannabis criminalised in this country continue to get weaker, while the public health benefits become more apparent.
 

Following the news that Germany is now following in the footsteps of countries like Canada and Spain in legalising cannabis, Jon Robson, CEO/founder of Mamedica, predicts the UK is likely to follow suit and introduce mainstream access to prescription-based treatments, he says: 
 

RelatedPosts on FintechZoom

OCR Labs Global’s Zero Bias AI™ Tech Awarded Further DIATF Certifications

Three New Associate Partners Join The Fintech & Payments Advisory Network

Equals Group announces a positive trading update with revenues up 59%

Global invoice financing group enables clothing giant to grow during times of economic recession

Revolutionizing Finance: STX Next on transforming the financial sector with Cutting-Edge AI & ML

Stubben Edge acquires Insurercore to expand tech offering

“I expect that over the next five years we will see mass adoption of private medical cannabis services in the UK, similar to what we have seen from German patients recently. At this point, the challenge is education and awareness however, once this barrier has been reduced, the medical market will inevitably pave the way for adult recreational sales as it has done in North America and in parts of Europe, where some countries are already legislating for sales by 2024.”

Who is eligible to use Mamedica’s services?

The service can be accessed by anyone, on a referral basis, that meets the health criteria and is over the age of 18. The service user will have to have had at least two other licensed medications or therapies for their condition, prior to accessing Mamedica, as prescribed by a GP or other licensed specialist. To be eligible, the patient should have no prior or existing diagnosis of Schizophrenia or Psychosis. 


How does the service work?

Upon referral, the client will be asked a series of questions to ensure they are eligible to access treatment. Should a person qualify, a specialist from the team will retrieve their Patient Records from existing NHS portals. Once all existing health records have been received, the patient will then be booked in for an initial consultation, followed by a follow-up consultation the next month, and will then receive their prescribed and bespoke treatment package delivered to their door. Patients can then expect to attend regular, quarterly meetings to monitor and assess the effectiveness of their treatment. 

About Mamedica 

Mamedica is a private clinic with a linked pharmacy which specialises in cannabis-based prescriptions (from oil to cannabis flower), for patients who have not found satisfactory results for their conditions with their existing medications across pain, psychiatry, neurology, palliative care and cancer.

Following a secure, private video consultation, if the consultant and the patient agree medical cannabis would be beneficial and safe, the medicines can be delivered directly to the patient’s door via next-day delivery service.

All medicines prescribed by Mamedica are produced and manufactured according to the pharmaceutical-grade EU-GMP (Good Manufacturing Practice), the most stringent in the world. Patients can rest easy that their medicines are not contaminated with pesticides or other adulterants.

Founded by Jon Robson, and launched in 2022, Mamedica aims to deliver a quality of service which is currently lacking in the medical cannabis sector. Mamedica puts patient safety, security and satisfaction at the forefront of every activity, using only the most high-calibre consultants and support staff as part of their team.

James Albert

James Albert

James Albert is a personal-finance analyst for FintechZoom and is based in New York. Contact: [email protected]

Related Posts

OCR Labs Global’s Zero Bias AI™ Tech Awarded Further DIATF Certifications

March 9, 2023

Three New Associate Partners Join The Fintech & Payments Advisory Network

February 15, 2023

Equals Group announces a positive trading update with revenues up 59%

February 15, 2023

Global invoice financing group enables clothing giant to grow during times of economic recession

February 15, 2023

Revolutionizing Finance: STX Next on transforming the financial sector with Cutting-Edge AI & ML

February 14, 2023

Stubben Edge acquires Insurercore to expand tech offering

January 20, 2023

Newly rebranded ONE Group partners with RegTech provider Know Your Customer

January 20, 2023

Private equity – private debt sector embraces self-serve technology – capital markets study

November 16, 2022

Zoho Finance platform hits 50% YoY Growth

November 16, 2022
Next Post

New data and robotics projects essential for viticulture

Response Comment: FCA proposes new rules to tackle greenwashing

Adyen launches Moments that Matter programme to unlock charity funding at scale

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

  • About Us
  • Advertise
  • Careers
  • Terms and Conditions
Call us: + 1 917 9939840

© 2016-2023 FINTECH ZOOM - WORLD FINANCE

No Result
View All Result
  • MARKETS
    • Trading
    • Stock Futures
    • Exchange Traded Fund (ETF)
    • Best Stocks To Buy Now
    • Penny Stocks
    • Forex Market
    • Bonds & Rates
    • Stock Market Guides
    • Commodities
      • Brent Crude Oil Price
      • WTI Crude Oil Price
    • Breaking Stock Market News
    • Reviews in Stock Market
    • Asian Markets
    • European Markets
    • US Markets
  • WORLD INDICES
    • DAX PERFORMANCE-INDEX
    • Russel 2000 (RUT)
    • STOXX Europe 600 (SXXP)
    • Euro Stoxx 50
    • CAC 40 Index (FCHI)
    • FTSE 100 Index
    • Nikkei 225 Index
    • HSI – Hang Seng Index
    • NSE Nifty 50 Index
    • NASDAQ Composite Index
    • Dow Jones (INDEXDJX: .DJI)
    • S&P 500 Index
    • ASX – Australian
    • Shanghai Index (SSE)
  • BUSINESS
  • CRYPTO
    • Metaverse
    • Tokens
    • Crypto Reviews
    • NFT : Non-Fungible Tokens
    • Stablecoins
    • Blockchain
    • Ethereum
    • Buy Bitcoin
    • Best Crypto
    • Bitcoin
    • Altcoins
  • MONEY
    • Insurance
    • Taxes
    • Mortgages
    • Loans
    • Personal Finances
    • Credit Cards
    • Interest Rates
  • BANKING
    • Banks Near Me
    • Payments
    • ATM Near me
    • Best Banks
    • Banks Guides
    • Transfer Money Online
    • Mobile Banking
    • Digital Bank
    • Secure Bank Login
  • TECH
    • Social Media
    • Login
    • Error Pages
    • Is It Down?
    • Download
    • Settings
  • LUXURY
    • Luxury Food & Drink
    • Luxury Cars
    • Luxury Style
    • Luxury Motors
    • Luxury Travel
    • Luxury Tech
  • LIFESTYLE
    • Travel
    • Entertainment
    • Health
    • Cars
    • Near Me
    • Life
    • Weather Tomorrow
  • INVESTMENT
    • Real Estate
    • Famous Investors
  • ABOUT US
    • Why Fintech Zoom?
    • What is FintechZoom?
    • Advertise with Us
    • Careers in FintechZoom
    • Fintech Zoom Logo
    • FintechZoom PRO
    • FintechZoom Contacts

© 2016-2023 FINTECH ZOOM - WORLD FINANCE

Are you sure want to unlock this post?
Unlock left : 0
Are you sure want to cancel subscription?